{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T15:24:51Z","timestamp":1789917891957,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["2021R1G1A1094252"],"award-info":[{"award-number":["2021R1G1A1094252"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["2022IP0062-1"],"award-info":[{"award-number":["2022IP0062-1"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.semarthrit.2024.152362","type":"journal-article","created":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T07:25:25Z","timestamp":1705130725000},"page":"152362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Continued JAK inhibitor treatment on the risk of recurrent herpes zoster reactivation in patients with immune-mediated inflammatory diseases: A nationwide population-based study in South Korea"],"prefix":"10.1016","volume":"65","author":[{"given":"Young-Eun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye-Jee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Hyun","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seonok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Jee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon Hwa","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Wook","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hyoung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8722-3124","authenticated-orcid":false,"given":"Seokchan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2024.152362_bib0001","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Herpes zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0002","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMcp013211","article-title":"Herpes zoster","volume":"347","author":"Gnann","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0003","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.cgh.2006.09.019","article-title":"Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease","volume":"4","author":"Gupta","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0004","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/acr.21928","article-title":"Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study","volume":"65","author":"Veetil","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0005","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/art.23112","article-title":"The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom","volume":"57","author":"Smitten","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0006","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.cgh.2018.05.024","article-title":"Increased risk of herpes zoster infection in patients with inflammatory bowel diseases in Korea","volume":"16","author":"Chang","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0007","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4078\/jrd.2017.24.4.220","article-title":"Risk of herpes zoster in patients with rheumatoid arthritis undergoing biologic disease-modifying therapy","volume":"24","author":"Kwon","year":"2017","journal-title":"J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0008","series-title":"Current topics in microbiology and immunology","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/82_2010_31","article-title":"VZV T cell-mediated immunity","author":"Weinberg","year":"2010"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0009","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/rheumatology\/key225","article-title":"Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Taylor","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0010","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0011","doi-asserted-by":"crossref","first-page":"151","DOI":"10.5217\/ir.2019.09154","article-title":"Recent updates on the basic mechanisms and pathogenesis of inflammatory bowel diseases in experimental animal models","volume":"18","author":"Mizoguchi","year":"2020","journal-title":"Intest Res"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0012","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1093\/ibd\/izy131","article-title":"Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib","volume":"24","author":"Winthrop","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0013","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/acr.23769","article-title":"Risk for herpes zoster in tofacitinib-treated rheumatoid arthritis patients with and without concomitant methotrexate and glucocorticoids","volume":"71","author":"Curtis","year":"2019","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0014","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5217\/ir.2020.00030","article-title":"Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis","volume":"19","author":"Shimizu","year":"2021","journal-title":"Intest Res"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0015","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0016","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0017","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s10067-022-06096-0","article-title":"Safety of JAK inhibitor use in patients with rheumatoid arthritis who developed herpes zoster after receiving JAK inhibitors","volume":"41","author":"Choi","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0018","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40744-021-00390-0","article-title":"Clinical management of herpes zoster in patients with rheumatoid arthritis or psoriatic arthritis receiving tofacitinib treatment","volume":"9","author":"Winthrop","year":"2022","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0019","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1093\/rheumatology\/keaa636","article-title":"Risk factors for herpes zoster in patients with rheumatic diseases: a nationwide cohort study in Korea","volume":"60","author":"Ryu","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0020","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jama.2013.1099","article-title":"Association between the initiation of anti\u2013tumor necrosis factor therapy and the risk of herpes zoster","volume":"309","author":"Winthrop","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0021","article-title":"Recurrence rate of herpes zoster and its risk factors: a population-based cohort study","volume":"34","author":"Kim","year":"2019","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0022","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4065\/mcp.2010.0618","article-title":"Herpes zoster recurrences more frequent than previously reported","volume":"86","author":"Yawn","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0023","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/14397595.2019.1583711","article-title":"Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: an integrated analysis of Phases 2 and 3 trials","volume":"30","author":"Harigai","year":"2020","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0024","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1136\/annrheumdis-2019-216852","article-title":"Infections in baricitinib clinical trials for patients with active rheumatoid arthritis","volume":"79","author":"Winthrop","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0025","first-page":"568","article-title":"Experience with tofacitinib in Canada: patient characteristics and treatment patterns in rheumatoid arthritis over 3 years","volume":"59","author":"Pope","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0026","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.15689","article-title":"Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry","volume":"51","author":"Biemans","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0027","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5217\/ir.2022.00007","article-title":"Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis","volume":"21","author":"Na","year":"2022","journal-title":"Intest Res"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0028","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0029","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0030","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0031","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0032","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20936059","article-title":"JAK inhibitors and infections risk: focus on herpes zoster","volume":"12","author":"Sunzini","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0033","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0034","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1086\/529448","article-title":"Use and limitations of varicella-zoster virus\u2013specific serological testing to evaluate breakthrough disease in vaccinees and to screen for susceptibility to varicella","volume":"197","author":"Breuer","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.semarthrit.2024.152362_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004901","article-title":"Varicella viruses inhibit interferon-stimulated JAK-STAT signaling through multiple mechanisms","volume":"11","author":"Verweij","year":"2015","journal-title":"PLoS Pathog"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224000039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224000039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:13:41Z","timestamp":1758734021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017224000039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":35,"alternative-id":["S0049017224000039"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152362","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Continued JAK inhibitor treatment on the risk of recurrent herpes zoster reactivation in patients with immune-mediated inflammatory diseases: A nationwide population-based study in South Korea","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152362","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152362"}}